阿达木单抗治疗眼部炎症的逐渐减量(HOT)研究
该回顾性多中心研究纳入328例非感染性葡萄膜炎患者,评估阿达木单抗减量后复发的预测因素。结果显示减量后复发率39.6%,平均复发时间44.7±61.7周。年轻患者、减量速度较快者复发风险更高,而减量前缓解期较长者复发风险更低。
要点
- 年轻患者减量后复发风险更高(每增加10岁,HR=0.88,P=.01)。
- 减量速度越快,复发风险越高(速度每增加1单位,HR=1.23,P<.0005)。
- 减量前缓解期每延长10周,复发风险降低(HR=0.97,P=.04)。
核心结论
- 阿达木单抗减量时应考虑患者年龄、种族及在阿达木单抗治疗下的疾病缓解持续时间。
- 作者建议采用缓慢的减量方案。
研究设计与样本
- 回顾性多中心研究,纳入328例非感染性葡萄膜炎患者,均接受阿达木单抗治疗后进行减量。
- 收集患者人口学特征、非感染性葡萄膜炎类型、发病及病程、减量前无活动期时长及减量方案。
- 主要结局指标为阿达木单抗减量后葡萄膜炎复发的独立预测因素。
主要发现
- 328例患者中女性占54.6%,平均年龄34.3岁。
- 从发病到开始阿达木单抗治疗的平均时间为35.2±70.1周。
- 在平均100.8±69.7周的无活动期后开始减量。
- 39.6%的患者出现复发,平均复发时间为44.7±61.7周。
- 复发患者平均年龄29.4岁 vs 未复发患者37.5岁(P=.0005),复发率在年轻受试者中显著更高(年龄每增加10岁,HR=0.88,P=.01)。
临床怎么用
- 作者认为,阿达木单抗减量时应考虑患者年龄、种族及在阿达木单抗治疗下的疾病缓解持续时间。
- 作者建议采用缓慢的减量方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess factors that impact the risk of relapse in patients with noninfectious uveitis (NIU) who undergo adalimumab tapering after achieving remission. DESIGN: Retrospective study. METHODS: In this multicenter study, patients with NIU were treated with adalimumab and subsequently tapered. Patient demographics, type of NIU, onset and duration of disease, the period of inactivity before tapering adalimumab, and the tapering schedule were collected. The primary outcome measures were independent predictors of the rate of uveitis recurrence after adalimumab tapering. RESULTS: Three hundred twenty-eight patients were included (54.6% female) with a mean age of 34.3 years. The mean time between disease onset and initiation of adalimumab therapy was 35.2 ± 70.1 weeks. Adalimumab tapering was commenced after a mean of 100.8 ± 69.7 weeks of inactivity. Recurrence was observed in 39.6% of patients at a mean of 44.7 ± 61.7 weeks. Patients who experienced recurrence were significantly younger than those without recurrence (mean 29.4 years vs 37.5 years, P = .0005), and the rate of recurrence was significantly higher in younger subjects (hazard ratio [HR] = 0.88 per decade of increasing age, P = .01). The lowest rate of recurrence was among Asian subjects. A faster adalimumab taper was associated with an increased recurrence rate (HR = 1.23 per unit increase in speed, P < .0005). Conversely, a more extended period of remission before tapering was associated with a lower rate of recurrence (HR = 0.97 per 10-weeks longer period of inactivity, P = .04). CONCLUSIONS: When tapering adalimumab, factors that should be considered include patient age, race, and duration of disease remission on adalimumab. A slow tapering schedule is advisable.
引用
- Pichi F, Smith SD, Goldstein DA, et al. The Humira in Ocular Inflammations Taper (HOT) Study. Am J Ophthalmol. 2023. PMID: 37734639. doi:10.1016/j.ajo.2023.09.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。